

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	09/990,909	
			Filing Date	November 16, 2001	
			First Named Inventor	Joan M. Fallon	
			Art Unit	1645	
Examiner Name	Virginia Allen Portner				
Sheet	1	of	2	Attorney Docket Number	41012-705.201

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)	MM-DD-YYYY		
	1.	US 2004/0057944 A1	03/25/2004	Galle et al.	
	2.	US 4,826,679	05/02/1989	Roy	
	3.	US 5,460,812	10/24/1995	Sipos	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	MM-DD-YYYY			
	4.	None.				

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER Initials if reference considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ²See Eureka Code of USPTO Patent Documents at www.uspto.gov or MPEP § 601.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.1). ⁴For Japanese patent documents, the indication of the year of the filing of the patent must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST 16 if possible. ⁶Applicant is to place a sheet mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to be used by the USPTO in processing an application. Confidentiality is governed by 35 U.S.C. 172 and 37 CFR 1.14. This collection is not to be used to make a copy to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any extension on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. TWO SETS SEND PETS OR LTR-601/2010 FORAM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PAT-ENT (1-800-761-6100) and select option 2

Attorney Docket No. 41012-705.201

- 1 -

4394739_2.DOC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MN/

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/990,909
				Filing Date	November 16, 2001
				First Named Inventor	Joan M. Fallon
				Art Unit	1645
Examiner Name	Virginia Allen Portner				
Sheet	2	of	2	Attorney Docket Number	41012-705.201

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	5.	Amendment dated 3/24/10 in Reply to Final Office Action dated 9/24/09 for US Application 12/046,252.			
	6.	Axcen Pharma Inc. Cdn Prescribing Information on VIOKASE Pancrelipase, USP tablets, powder. 2000: 1-3.			
	7.	DOCKTER et al. Determination of chymotrypsin in the feces by a new photometric method. Padiatr Padoi. 1985; 20(3):257-265.			
	8.	HEIJERMAN, et al. Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis. Ann Intern Med. 1991 Feb 1;114(3):200-1.			
	9.	KACHRIMANIS, et al. Tensile strength and disintegration of tableted silicified microcrystalline cellulose: influences of interparticle bonding. J Pharm Sci. 2003 Jul;92(7):1489-501.			
	10.	MARLJCZ et al. Determination of chymotrypsin in the stool in the diagnosis of chronic pancreatitis. Wiadomosci lekarskie. 1988; 41(11):704-707. (in Polish with English abstract/summary)			
	11.	MITCHELL, et al. Comparative trial of viokase, pancreatin and Pancrease pancrelipase (enteric coated beads) in the treatment of malabsorption in cystic fibrosis. Aust Paediatr J. 1982 Jun;18(2):114-7.			
	12.	Notice of Allowance dated 04/15/11 for US Application 12/487,865.			
	13.	Office Action dated 03/29/11 for US Application 12/054,343.			
	14.	Office Action dated 03/30/11 for US Application 12/786,739.			

Examiner Signature	/Albert M Navarro/	Date Considered	05/19/2011
--------------------	--------------------	-----------------	------------

*EXAMINER: initial if reference forwarded, whether or not citation is in conformance with MPEP 809. Draw line through citations of not in conformance and not considered. Include copy of this item with next communication to applicant.
 *Applicant: a unique card for identification number (signature). *Applicant is to place a checkmark here if English language translation is attached.
 This collection of information is required by 37 CFR 1.48. This information is required to obtain or retain a benefit by the public which is to be paid by the USPTO to persons on applications. This collection of information is required by 35 U.S.C. 122 and 37 CFR 1.15. This collection is submitted to the USPTO to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the scope of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1480, Alexandria, VA 22314-1480. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1480, Alexandria, VA 22314-1480.
 If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-755-9199) and select option 2.